A trial of BKM120 (buparlisib), a small-molecule inhibitor of the PI3K signaling pathway, demonstrated inhibition of the PI3K/AKT/mTOR signaling, which is often overactive in tumor cells [37]. This evidence concerns the gene AKT1 and neoplasm.